When will CMS announce the addition of GLP-1 drugs for obesity to Part D?
4.0 pts (24h)Política de EE. UU.One-Off1a
KalshiComprobar disponibilidadKYC requeridoDatos de resolución verificadosBien calibradoPunto medio del libro seleccionado
Before Jan 20, 2029 · —
Cargando el libro seleccionado…
Libro recibido (no hora de cotización del mercado): —
Precio guardado
Before Jan 20, 2029 Compra–venta guardada50%–53%Recopilado: Última operación: 53% · Hora de la operación desconocidaPrecios como porcentaje del pago, antes de comisiones; estas observaciones guardadas no son cotizaciones ejecutables.Líder entre 3 opciones
Before Jan 20, 2029 Compra–venta guardada50%–53%Recopilado: Última operación: 53% · Hora de la operación desconocidaPrecios como porcentaje del pago, antes de comisiones; estas observaciones guardadas no son cotizaciones ejecutables.Calidad del mercado
47 / 100
Baja calidadVolumen 24h
8,2 €
Interés abierto
4,9 mil €
Interés abierto medioCompra / Venta
— / —
Before Jan 20, 2029Spread
—
Datos de mercado
Actualizado hace 34 minutos
24 ago 26, 14:00 UTC1 ene 28, 4:59 UTC
El gráfico y los cambios muestran probabilidades históricas guardadas, no el libro seleccionado en directo.
Tendencias
Fila seleccionada: punto medio del libro. Otras filas: referencias guardadas, posiblemente normalizadas; los cambios de 24h usan el historial guardado.
Condiciones de la plataforma
Fuente: Kalshi
Estas condiciones son informativas; las operaciones simuladas de CoinRithm siguen sus propias reglas.
- Cierre anticipado:
- Sí
- Plazo de liquidación:
- 30m (informativo)
Profundidad de mercado · Before Jan 20, 2029
Cargando el libro seleccionado…
Libro recibido (no hora de cotización del mercado): —
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Nobel Prize awarded for Ozempic (or GLP-1 drugs) by 2030?
Manifold MarketsWhat fraction of US adults will regularly take GLP-1 drugs in 2030?
Manifold MarketsWhich party will win the U.S. House?
KalshiUS-Iran ceasefire continues through which date?
Polymarket2026 Midterms: Congress Balance of Power?
KalshiWhich party will win the House in 2026?
PolymarketReglas
If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 20, 2029, then the market resolves to Yes.
- GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part D sponsors through the Health Plan Management System. Where the White House or HHS makes the determination, the CMS document adopting it resolves this market, on the date of that document. The following do NOT resolve this market to YES: A CMS communication that discusses, studies or reports on such coverage. A proposed rule or a request for applications, which propose coverage rather than provide it. An action that considers the change and declines to make it. The Medicare GLP-1 Bridge, or extending or replacing it, because it sits outside the Part D benefit. An announcement covering only the Medicaid portion of the BALANCE Model. Coverage of a single drug, or of a subset of Part D enrollees, is sufficient. The announcement date governs, not the date coverage takes effect.
Reglas de cada resultado
- Before Jan 20, 2029
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 20, 2029, then the market resolves to Yes.
- Before Jan 1, 2028
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2028, then the market resolves to Yes.
- Before Jan 1, 2027
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2027, then the market resolves to Yes.